 Oncolytics Biotech Inc. NASDAQ: ONCY TSX: ONC, today provided a recap of a Key Opinion Leader KOL call sponsored by Canaccord Genuity and held on June 2, 2020. The call focused on recently announced clinical data from Oncolytics AWARE-1 study presented at the European Society for Medical Oncology ESMO Breast Cancer Virtual Meeting 2020 and highlighted the ability of pelareorep to induce a pro-inflammatory tumor microenvironment across multiple breast cancer subtypes. 